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ABSTRACT
Background Adverse drug events may occur as a
result of drug–drug interactions (DDIs). Infor-
mation technology (IT) systems can be an import-
ant decision-making tool for healthcare workers to
identify DDIs.
Objective The aim of the study is to analyse drug
prescriptions in ourmain hospital units, in order to
measure the incidence and severity of potential
DDIs. The utility of clinical decision-support sys-
tems (CDSSs) and computerised physician order
entry (CPOE) in term of alerts adherence was also
assessed. DDIs were assessed using aMicromedex1
healthcare series database.
Methods The system, adopted by the hospital,
generates alerts for prescriptions with negative
interactions and thanks to an ’acknowledgement
function’ it is possible to verify physician adherence
to alerts. This function, although used previously,
became mandatory from September 2010. Phys-
ician adherence to alerts and mean monthly inci-
dence of potential DDIs in analysed units, before
and after the mandatory ‘acknowledgement func-
tion’, were calculated.
Results The intensive care unit (ICU) registered
the greatest incidence of potential DDIs (49.0%),
followed by the abdominal surgery unit and dialysis
(43.4 and 42.0%, respectively). The cardiothoracic
surgery unit (41.6%), step-down unit (38.3%) and
post-anaesthesia care unit (30.0%) were compar-
able. The operating theatre and endoscopy regis-
tered the fewest potential DDIs (28.2 and 22.7%,
respectively). Adherence to alerts after the ‘acknow-
ledgement function’ increased by 25.0% in the ICU,
54.0% in the cardiothoracic surgery unit, 52.5% in
the abdominal surgery unit, 58.0% in the step-
down unit, 67.0% in dialysis, 51.0% in endoscopy
and 48.0% in the post-anaesthesia care unit. In the
operating theatre, adherence to alerts decreased
from 34.0 to 30.0%. The incidence of potential
DDIs aftermandatory use of the ’acknowledgement
function’ decreased slightly in endoscopy (–2.9%),
the abdominal surgery unit (–2.7%), dialysis (–1.9%)
and the step-down unit (–1.4%).
Conclusions Improving DDI alerts will improved
patient safety by more appropriately alerting clin-
icians.
Keywords: clinical decision-support system, com-
puterised physicians order entry, drug interactions
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Introduction
Drug–drug interactions (DDIs) are a complex clinical
problem that should draw the attention of all health-
care workers, especially physicians and pharmacists
directly involved in choosing the right therapy for
patients. Adverse drug events (ADEs) may occur as a
result of potential DDIs (p-DDIs). Oftentimes they
are predictable and preventable.1,2 These adverse events
result in increased rates of hospitalisation, increased
lengths of stay, and contribute to patient morbidity
and mortality.1,3,4 Several factors can complicate the
possibility of identifying and managing p-DDIs. For
example, the use of polypharmacy, particularly com-
mon among older adults, increases the risk of having
adverse drug reactions and/or interactions.5 A study of
4431 hospitalisations revealed an average of six drugs
per patient.6 Another study, on 907 patients, revealed
an average of 9.6 drugs per patient.7 The more associ-
ations there are among diﬀerent drugs, the greater the
chance that their safety proﬁles will be lowered. 8–10
Other factors, such as gender, age, genetics, comor-
bidities, and state of health are also linked to the risk of
DDIs.11,12
Themost vulnerable patients are those with chronic
diseases that require long-termmultitherapy; patients
with liver or kidney failure who are using drugs
included in the group at risk of interaction, and geriatric
and paediatric patients, whose metabolic activity is
signiﬁcantly related to age.13–19 To ensure safe therapy
for these patients, appropriate drug prescription is
required. In the age of information technology (IT)
systems, the use of electronic health records and
computerised physician order entry (CPOE) can be
an eﬃcacy tool to promote patient safety.20–21 Clinical
decision-support systems (CDSSs) are an additional
component of CPOE systems that can be utilised and
have been deﬁned as ‘computer software employing
a knowledgebase designed for use by a clinician
involved in patient care, as a direct aid to clinical
decision making’.22 CDSSs added to CPOE systems
guide prescribers on appropriate dosing and alert them
to duplicate therapies, drug allergies and DDIs.23 So
patient safety, quality and eﬃciency of care can be
improved.24
Although CDSSs provide several beneﬁts, there are
also limitations as a result of which p-DDI alerts
receive no response from physicians.25–28 Unclear
clinical signiﬁcance, alert fatigue and database rating
inconsistencies can, at times, lead to low p-DDI alert
acceptance by prescribers.1
The goal of this study was to analyse drug prescrip-
tions in our main hospital units, in order to measure
the incidence and severity of p-DDIs. In addition, the
utility of CDSS and CPOE in terms of alerts adherence
was assessed.
Method
This retrospective observational study was carried out
at ISMETT, a 90-bed transplant hospital in Palermo,
Italy. All prescriptions in the intensive care unit (ICU),
step-down unit (SDU), cardiothoracic surgery unit
(CSU), abdominal surgery unit (ASU), dialysis, en-
doscopy, operating theatre (OT) and post-anaesthesia
care unit (PACU), from June 2010 to December 2010,
were analysed for p-DDIs. All interactions were
assessed using the Micromedex1 Healthcare Series
database, and severity of p-DDI was analysed accord-
ing to the decisional support system classiﬁcation
(Table 1) in the Sunrise1Eclipsys electronic medical
record.
The mean incidence of p-DDIs for each unit was
calculated. The value was obtained by dividing the
mean number of p-DDIs for each unit by the mean
number of drug prescriptions in that unit for each
period of evaluation.
The program developed and adopted by our hos-
pital allows physicians to obtain helpful information
on drug prescriptions. It also generates alerts in case of
active agents with negative interactions. It is possible
to verify adherence to p-DDI alerts through the elec-
tronic medical record. This veriﬁcation was made
What is known
. Alerts can improve the quality and safety of physician prescriptions.
. The literature has reported that many alerts are frequently cancelled and ignored.
. Alerts can aid to prevent potential drug–drug interactions (p-DDIs) and possible related adverse reactions.
What this paper adds
. ‘Acknowledgement function’ mandatory use has demonstrated greater adherence to warning systems.
. It is necessary to program software to reduce alert fatigue highlighting only severe alerts.
. In our setting, most p-DDIs are referred to few drugs and this knowledge facilitates their management in
clinical practice.
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possible thanks to an ‘acknowledgement function’,
which carries the electronic signature of the physician
(statement read yes/no) indicating his or her acknow-
ledgement of the interactions. Statement read ‘yes’
means the physician displayed and read the alert and is
aware that the combination drug choice is potentially
harmful for the patient. This function, in the ﬁrst
period of study, was not required, so physicians could
proceed with the prescription without responding to
any alert. Beginning in September 2010, the ‘acknow-
ledgement function’ became mandatory, prompting
physicians to consider the alert. ‘Acknowledgement
function’ can aid physicians to choose, when possible,
a therapeutic alternative. For each unit, the adherence
to alerts on the part of physicians and the incidence of
p-DDIs, before and after introduction of the ‘acknow-
ledgement function’, were compared to verify the
function suitability as a strategy for improving quality
of the process.
A pivot table was used as an analytical and reporting
instrument in which the available data were processed
by type of drug, unit and number of p-DDIs, and
physician adherence to the alerts.
Results
The ICU registered amean of 1053 p-DDIs for amean
of 2152 prescriptions per month (49.0%), followed by
ASU and dialysis with an average of 604 and 15.6 p-
DDIs, respectively, for a mean of 1390 and 37 pre-
scriptions (43.4 and 42.0%, respectively). CSU regis-
tered a mean of 520 p-DDIs for a mean of 1248
prescriptions monthly (41.6%), SDU registered a
mean of 596 p-DDIs for a mean of 1555 prescriptions
monthly (38.3%) and PACU registered a mean of 99
p-DDIs for a mean of 332 prescriptions per month
(30.0%).
OT and endoscopy, the smallest units, registered a
mean of 166 p-DDIs for a mean of 588 prescriptions
monthly (28.2%), and 8.8 p-DDIs for a mean of 39
prescriptions monthly (22.6%), respectively. Overall
analysis of prescriptions identiﬁed the top ﬁve drugs
responsible for p-DDIs in the main units in our
hospital: furosemide (1768 p-DDIs), tacrolimus
(1496 p-DDIs), omeprazole (801 p-DDIs), sodium-
fructose-1.6-diphosphate (428 p-DDIs) and warfarin
(395 p-DDIs). Although these interactions are known
in the literature, the subject is so vast and growing
both for mechanisms that determine p-DDIs and
appearance on the market of new drugs, that remem-
bering their importance is never enough.
In the ﬁrst period of study (June 2010 to August
2010) adherence to alerts was 70.0% in the ICU, 41.0%
in the CSU, 43.0% in the ASU, 36.0% in the SDU,
29.0% in dialysis, 10.0% in endoscopy and 42.0% in
the PACU. From September 2010 to December 2010,
after introduction of the mandatory reading of alerts
for physicians, a marked improvement was found:
95.0% in the ICU, 95.0% in the CSU, 95.5% in the
ASU, 94.0% in the SDU, 96.0% in dialysis, 61.0% in
endoscopy and 90% in the PACU. In OT adherence to
alerts decreased from 34.0 to 30.0%. A positive trend
was observed (reduction of p-DDIs) in four units,
whichmight be due to the greater adherence to warning
systems. The better results were in endoscopy and ASU
with a reduction of 2.9 and 2.7%, respectively, fol-
lowed by dialysis and SDUwith a reduction of 1.9 and
1.4%, respectively (Table 2).
Considering the total number of drug prescriptions
(51 393) in the study period (seven months), the total
number of p-DDIs was 21 447, or 41.7%.
Table 1 Multum drug database of alert severity levels
Alert severity levels Deﬁnitions Reported lesions
Major Monitor closely
Contraindicated
Generally avoid
Death or life-threatening lesions
Moderate Monitor
Generally avoid
Adjust dosing interval
Adjust dosing
Additional contraception
recommended
Severe lesions, not lethal
Minor None Clinical eﬀects insigniﬁcant,
minor or favourable
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Discussion
Principal ﬁndings
DDIs are a complex and controversial part of phar-
macology. Our study showed that almost 42.0% of
drugs prescribed in the analysed period and in the
units reviewed interacted with other drugs prescribed
for therapy. This may be because many of our patients
are seriously ill and require multidrug therapies. Of
the eight units evaluated, the ICU registered the
greatest number of p-DDIs, followed by ASU and
dialysis. CSU, SDU and PACU are comparable with
the larger units in terms of number and type of
interactions, whereas OT and endoscopy registered
the fewest p-DDIs.
Another important result that emerged from the
data was the increasing adherence on the part of
physicians to the software alerts. More speciﬁcally,
ASU, SDU and dialysis are among the units where
there is more adherence. Eﬀectively, in these units,
there was a decrease, although low, in the incidence of
p-DDIs from 42 to 39%. The exception was the OT in
which adherence is very low. It was assumed that this
may be due to unforeseen emergency situations that
often occur. It is right, also, to remember that in the
OT there is always an anaesthetist present to carefully
monitor the patient. This study has identiﬁed the ﬁve
drugs more involved in p-DDIs in our hospital, this
could be a starting point for all healthcare workers
responsible for medication safety.
It is hard to predict the clinical impact of p-DDIs.
As a result, the rational and appropriate use of multi-
drug therapies is a key factor of prevention. Often
p-DDIs cannot be avoided because of the need to use
drugs in combination, especially when there are no
therapeutic alternatives. This limitation is mitigated by
constant patient monitoring of vital signs and drug
blood levels. Despite a small reduction in p-DDIs,
implementing computerised alerts can be an eﬀective
way of supporting clinical decision making, allowing
clinicians to see all possible p-DDIs and evaluate their
impact in terms of potential risks and beneﬁts.
Introducing alerts does not replace physician assess-
ment: patients cannot be deprived of therapies based
solely on the risk of interactions, but all alternatives
must be taken into account. In conclusion, it is import-
ant tomake alerts as eﬀective as possible. In this context
new technologies can aid physicians and improve pre-
scribing safety. However, there is yet the need to
determine the most eﬀective way to deliver alerts in
order to eliminate possible unnecessary alerts.
Implications for practice
Although a slight decrease in the incidence of p-DDIs
was observed, development of the ‘acknowledgement
function’ has increased physician adherence to alerts.
This is an important starting point for advanced forms
of CDSSs that should support the physician in
identifying important p-DDIs without generating
clinically irrelevant alerts.
Comparisons with the literature
As widely addressed by Vaziri et al,29 the prescribing
alert systems used in primary care practice often have
Table 2 Incidence of potential DDIs before and after introducing the ‘acknowledgement
function’
June/July/August
interactions (%)
September/October/
November/December
interactions (%)
~ (%)
ICU 47.0 50.4 3.4
SDU 39.2 37.8 –1.4
CTU 41.0 42.4 1.4
ASU 45.0 42.3 –2.7
OT 27.2 28.7 1.5
PACU 27.1 31.9 4.8
Dialysis 43.4 41.5 –1.9
Endoscopy 24.4 21.5 –2.9
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low speciﬁcity and low utility. In fact, alerts are often
ignored, or viewed uncritically by physicians, who rely
on their experience, and on a careful monitoring of
patients.30 Healthcare IT leaders are working to resolve
this important issue to everyone’s beneﬁt, increasingly
implementing systems that put out only eﬀective alerts
or apply alerting strategies.31
Limitations of the method
Alerts for interaction have a number of important
limitations. Checking drug interactions can generate
large numbers of clinically insigniﬁcant alerts (low
severity) that clinicians might ignore. We experienced
this at our hospital because too many p-DDIs of low
priority were displayed, leading the user to reject the
entire application. We urgently need better evidence
on which p-DDIs are important. The strength of the
alerts should be related to the severity and importance
of the interactions, only in this way ‘alert fatigue’ may
decrease.31
Calls for further research
CDSSs must support rather than impede, clinical
work-ﬂows through speedy, available and usable al-
gorithms that provide parsimonious, clear, concise
and actionable warnings and advice. A potential
solution beyond using alerts in or not in this situation
would be continuing to deliver decision support but,
when alerting, ask clinicians explicitly whether the
patient has an infection that requires treatment for
which there is no other good option. Alerts should
present the names of the interacting drugs, a brief
description of the interaction, optional link to more
detailed information and a menu for appropriate
actions in response to the alert.
Conclusion
p-DDIs might cause an important amount of harm,
which is largely preventable. The main goal for all
healthcare workers is to participate in a system that
ensures patient safety, and this should include evalu-
ation of severe p-DDIs. There is a need for modiﬁ-
cation of DDI alerting systems to increase alert
acceptance and maximise the beneﬁts of this tech-
nology. For this reason, the optimisation of resources
by improving DDI alerts through careful and constant
monitoring of therapies can ensure safer and more
appropriate prescriptions.
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